0001171843-23-005235.txt : 20230810 0001171843-23-005235.hdr.sgml : 20230810 20230810171603 ACCESSION NUMBER: 0001171843-23-005235 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230810 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230810 DATE AS OF CHANGE: 20230810 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Predictive Oncology Inc. CENTRAL INDEX KEY: 0001446159 STANDARD INDUSTRIAL CLASSIFICATION: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842] IRS NUMBER: 331007393 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36790 FILM NUMBER: 231160683 BUSINESS ADDRESS: STREET 1: 91 43RD STREET STREET 2: SUITE 110 CITY: PITTSBURGH STATE: PA ZIP: 15201 BUSINESS PHONE: 412-432-1500 MAIL ADDRESS: STREET 1: 91 43RD STREET STREET 2: SUITE 110 CITY: PITTSBURGH STATE: PA ZIP: 15201 FORMER COMPANY: FORMER CONFORMED NAME: Precision Therapeutics Inc. DATE OF NAME CHANGE: 20180314 FORMER COMPANY: FORMER CONFORMED NAME: Precision Therapeutic Inc. DATE OF NAME CHANGE: 20180208 FORMER COMPANY: FORMER CONFORMED NAME: Skyline Medical Inc. DATE OF NAME CHANGE: 20130807 8-K 1 f8k_081023.htm FORM 8-K
0001446159 false 0001446159 2023-08-10 2023-08-10 0001446159 dei:FormerAddressMember 2023-08-10 2023-08-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_____________________

 

FORM 8-K

_____________________

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event Reported): August 10, 2023

 

Predictive Oncology Inc.

(Exact Name of Registrant as Specified in Charter)  

 

Delaware 001-36790 33-1007393
(State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification Number)

 

 

91 43rd Street, Suite 110, Pittsburgh, Pennsylvania 15201

(Address of Principal Executive Offices) (Zip Code)

 

(651) 389-4800

(Registrant's telephone number, including area code)

 

2915 Commers Drive, Suite 900, Eagan, Minnesota 55121

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading symbol(s) Name of each exchange on which registered
Common stock, $0.01 par value POAI Nasdaq Capital Market

 

 

 

Item 2.02. Results of Operations and Financial Condition.

 

On August 10, 2023, Predictive Oncology Inc. issued a press release attached hereto as Exhibit 99.1 announcing its financial results for the three months ended June 30, 2023.

 

Item 9.01. Financial Statements and Exhibits.

 

(a) Not applicable.

 

(b) Not applicable.

 

(c) Not applicable.

 

(d) Exhibits

 

Exhibit No.  Description
    
99.1   Press Release dated August 10, 2023
104  Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 Predictive Oncology Inc.
    
    
Date: August 10, 2023By: /s/ Bob Myers
   Bob Myers
   Chief Financial Officer

 

 

 EX-99.1 2 exh_991.htm EXHIBIT 99.1 EdgarFiling

EXHIBIT 99.1

Predictive Oncology Reports Second Quarter 2023 Financial Results and Provides Business Update

Company to host investor call and webcast today, August 10th, at 5:30pm EDT

PITTSBURGH, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI), a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, CLI laboratory and GMP facility, to accelerate oncologic drug discovery and enable drug development, today reported financial and operating results for the three and six months ended June 30, 2023, and provided a corporate update. The company reported a net loss of $3.9 million on total net revenue of $0.5 million for the second quarter 2023.

Q2 2023 and Recent Highlights:

  • Initiated PEDAL-Cancer Research Horizons collaboration for the analysis of drug compounds;
  • Initiated strategic collaboration with Cvergenx to identify novel molecules and compounds and the repurposing of radioprotective or radiosensitizing drugs;
  • Delivered a presentation on the importance of addressing patient heterogeneity in drug discovery and the advantages of leveraging active machine learning at the Bio International Convention in Boston in June; met with more than 30 biopharmaceutical development customer prospects and further expanding Predictive Oncology’s sales pipeline;
  • Established new Business Advisory Board and announced first two appointments: Dr. Bernard Harris and Andrew Einhorn;
  • Appointed pharma, biotech and digital health industry veteran, Dr. Veen Rao, to the Company’s Board of Directors;
  • Relocated corporate headquarters to Pittsburgh, PA from Eagan, MN.

“We are very pleased with the steady progress that we have made since our last quarterly update, both advancing current PEDAL relationships with CRH, Cvergenx and others, while in parallel building our pipeline as more drug developers – both biopharmaceutical companies as well as research institutions – see the value that only Predictive Oncology can bring to the early drug discovery process,” said Raymond F. Vennare, Chief Executive Officer and Chairman of Predictive Oncology. “With our unique set of assets and capabilities that clearly set us apart from other AI-focused drug discovery companies, including our extensive biobank of more than 150,000 tumor samples, combined with our CLIA lab, we can validate our predictions in wet lab experiments in a setting that introduces patient heterogeneity into the earliest phases of drug discovery. We are the only company capable of doing this, and the results of these experiments can significantly increase the chances of later-stage clinical success by our customers.”

“The tangible impact of our presence at Bio International this year was measurable. The sustained exposure and global reach afforded by conferences like this will prove critical to our long-term success as we continue to raise awareness of Predictive Oncology as the ‘partner of choice’ for drug developers looking to streamline their drug discovery efforts with AI and machine learning capabilities. I am very pleased with our progress to date and look forward to meaningful developments with current and prospective customers in the back half of the year and into 2024,” Mr. Vennare concluded.

Q2 2023 Financial Summary:

  • Concluded the second quarter of 2023 with $14.8 million in cash and cash equivalents, compared to $22.1 million as of December 31, 2022, and $14.7 million in Stockholder’s Equity, compared to $21.8 million as of December 31, 2022.
  • Loss per common share for Q2 2023 was $0.98, as compared to $2.89 for the second quarter of 2022.

Q2 2023 Financial results

  • Predictive Oncology recorded revenue of $490,110 in the second quarter of 2023, compared to $371,591 in 2022. Sales of Streamway related products and services by our Eagan operating segment were responsible for the majority of the revenue.
  • Gross profit margin increased to 67% during the three months ended June 30, 2023 as compared to 64% in the comparable period in 2022 due to sales mix and higher margins on disposables for Streamway machines.
  • G&A expenses increased by $352,831 to $2,704,527 for the three months ended June 30, 2023, compared to $2,351,696 for the same period in 2022. The increase was primarily due to increased investor relations fees related to the reverse stock split, office rent and other general and administrative expenses.
  • Operations expense increased by $83,929 to $993,042 for the three months ended June 30, 2023 compared to $909,113 for the comparable three months ended in 2022, primarily due to higher cloud computing expenses, offset by decreases in expenses related to the closure of the offices of the Company’s former wholly-owned subsidiaries.
  • Sales and marketing expenses increased by $158,081 for the three months ended June 30, 2023, to $429,103, compared to $271,022 for the same period in 2022. The increase was due primarily due to the increase in marketing and business development staff hired after June 20, 2022.
  • Net cash used in operating activities was $7,002,033 and $6,427,806 for the six months ended June 30, 2023 and June 30, 2022, respectively. Cash used in operating activities increased in the 2023 period primarily due to an increase in operating expenses and changes in working capital.

Conference call and webcast details:

Predictive Oncology management will host an investor conference call and webcast today, August 10th, at 5:30pm EDT.

To participate in the call, investors and analysts should dial 1-877-407-3982 (domestic) or 1-201-493-6780 (international) and reference conference ID 13739784.

To access the Call Me™ feature, which eliminates the need to wait for a call operator, please click here.

The live webcast of the call can be accessed here.

Forward-Looking Statements:

Certain matters discussed in this release contain forward-looking statements. These forward-looking statements reflect our current expectations and projections about future events and are subject to substantial risks, uncertainties and assumptions about our operations and the investments we make. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future revenue and financial performance, projected costs, prospects, plans and objectives of management are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “would,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Our actual future performance may materially differ from that contemplated by the forward-looking statements as a result of a variety of factors including, among other things, factors discussed under the heading “Risk Factors” in our filings with the SEC. Except as expressly required by law, the Company disclaims any intent or obligation to update these forward-looking statements.

Investor Relations Contact: 
Tim McCarthy, CFA
LifeSci Advisors, LLC 
tim@lifesciadvisors.com

 
PREDICTIVE ONCOLOGY INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
 
  June 30,
2023		 December 31,
2022
ASSETS        
Current assets:        
Cash and cash equivalents $14,763,745  $22,071,523 
Accounts receivable  430,849   331,196 
Inventories  393,698   430,493 
Prepaid expense and other assets  381,233   526,801 
Total current assets  15,969,525   23,360,013 
         
Property and equipment, net  1,548,805   1,833,255 
Intangibles, net  266,183   253,865 
Lease right-of-use assets  3,008,397   211,893 
Other long-term assets  174,096   75,618 
Total assets $20,967,006  $25,734,644 
         
LIABILITIES AND STOCKHOLDERS' EQUITY        
Current liabilities:        
Accounts payable $1,013,481  $943,452 
Accrued expenses and other liabilities  1,650,300   2,229,075 
Derivative liability  5,572   13,833 
Contract liabilities  627,896   602,073 
Lease liability  466,087   94,237 
Total current liabilities  3,763,336   3,882,670 
         
Lease liability – net of current portion  2,498,613   86,082 
Total liabilities  6,261,949   3,968,752 
         
Stockholders’ equity:        
Total stockholders' equity  14,705,057   21,765,892 
         
Total liabilities and stockholders' equity $20,967,006  $25,734,644 
 

                      

PREDICTIVE ONCOLOGY INC.
CONDENSED CONSOLIDATED STATEMENTS OF NET LOSS
(Unaudited)
 
  Three Months Ended
June 30,		 Six Months Ended
June 30,
   2023   2022   2023   2022 
Revenue $490,110  $371,591  $730,005  $686,159 
Cost of goods sold  159,761   134,075   279,900   243,518 
Gross margin  330,349   237,516   450,105   442,641 
                 
General and administrative expense  2,704,527   2,351,696   5,040,511   4,775,347 
Operations expense  993,042   909,113   1,871,560   1,800,184 
Sales and marketing expense  429,103   271,022   799,340   575,489 
Loss on impairment of goodwill  -   7,231,093   -   7,231,093 
Loss on impairment of property and equipment  162,905   -   162,905     
Total operating loss  (3,959,228)  (10,525,408)  (7,424,211)  (13,939,472)
Other income  28,552   41,047   70,780   83,477 
Other expense  -   (2,217)  -   (3,206)
Gain on derivative instruments  7,308   95,254   8,261   97,162 
Net loss $(3,923,368) $(10,391,324) $(7,345,170) $(13,762,039)
                 
Net loss per common share - basic and diluted $(0.98) $(2.89) $(1.84) $(4.00)
                 
Weighted average shares used in computation – basic and diluted  3,996,512   3,589,684   3,982,384   3,441,546 

 

EX-101.SCH 3 poai-20230810.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 poai-20230810_def.xml XBRL DEFINITION FILE EX-101.LAB 5 poai-20230810_lab.xml XBRL LABEL FILE Entity Addresses, Address Type [Axis] Former Address [Member] Entity Addresses [Table] Entity Addresses [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 poai-20230810_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Cover
Aug. 10, 2023
Entity Addresses [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 10, 2023
Entity File Number 001-36790
Entity Registrant Name Predictive Oncology Inc.
Entity Central Index Key 0001446159
Entity Tax Identification Number 33-1007393
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 91 43rd Street
Entity Address, Address Line Two Suite 110
Entity Address, City or Town Pittsburgh
Entity Address, State or Province PA
Entity Address, Postal Zip Code 15201
City Area Code (651)
Local Phone Number 389-4800
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, $0.01 par value
Trading Symbol POAI
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Former Address [Member]  
Entity Addresses [Line Items]  
Entity Address, Address Line One 2915 Commers Drive
Entity Address, Address Line Two Suite 900
Entity Address, City or Town Eagan
Entity Address, State or Province MN
Entity Address, Postal Zip Code 55121

XML 8 f8k_081023_htm.xml IDEA: XBRL DOCUMENT 0001446159 2023-08-10 2023-08-10 0001446159 dei:FormerAddressMember 2023-08-10 2023-08-10 iso4217:USD shares iso4217:USD shares 0001446159 false 8-K 2023-08-10 Predictive Oncology Inc. DE 001-36790 33-1007393 91 43rd Street Suite 110 Pittsburgh PA 15201 (651) 389-4800 2915 Commers Drive Suite 900 Eagan MN 55121 false false false false false Common stock, $0.01 par value POAI NASDAQ EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 2 23 1 false 1 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://predictive-oncology.com/role/Cover Cover Cover 1 false false All Reports Book All Reports f8k_081023.htm exh_991.htm poai-20230810.xsd poai-20230810_def.xml poai-20230810_lab.xml poai-20230810_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "f8k_081023.htm": { "axisCustom": 0, "axisStandard": 1, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 28 }, "contextCount": 2, "dts": { "definitionLink": { "local": [ "poai-20230810_def.xml" ] }, "inline": { "local": [ "f8k_081023.htm" ] }, "labelLink": { "local": [ "poai-20230810_lab.xml" ] }, "presentationLink": { "local": [ "poai-20230810_pre.xml" ] }, "schema": { "local": [ "poai-20230810.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 64, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 1, "nsprefix": "POAI", "nsuri": "http://predictive-oncology.com/20230810", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "f8k_081023.htm", "contextRef": "AsOf2023-08-10", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://predictive-oncology.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "f8k_081023.htm", "contextRef": "AsOf2023-08-10", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 1, "tag": { "dei_AddressTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An entity may have several addresses for different purposes and this domain represents all such types." } } }, "localname": "AddressTypeDomain", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r14", "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityAddressesAddressTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.", "label": "Entity Addresses, Address Type [Axis]" } } }, "localname": "EntityAddressesAddressTypeAxis", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_EntityAddressesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Entity Addresses [Line Items]" } } }, "localname": "EntityAddressesLineItems", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_EntityAddressesTable": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Container of address information for the entity", "label": "Entity Addresses [Table]" } } }, "localname": "EntityAddressesTable", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_FormerAddressMember": { "auth_ref": [ "r13", "r16" ], "lang": { "en-us": { "role": { "documentation": "Former address for entity", "label": "Former Address [Member]" } } }, "localname": "FormerAddressMember", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "xbrltype": "domainItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://predictive-oncology.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 10-Q", "Number": "249", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Form 8-K", "Number": "249", "Publisher": "SEC", "Section": "308", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r20": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r21": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0001171843-23-005235-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001171843-23-005235-xbrl.zip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ⅅ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end